Vitamin D3 Supplementation in Dialysis Patients
- Registration Number
- NCT01312714
- Lead Sponsor
- Regional Hospital Holstebro
- Brief Summary
Vitamin D deficiency is highly prevalent among dialysis patients, and has been associated with cardiovascular risk factors such as increased aortic pulse wave velocity, blood pressure, inflammation, and brain natriuretic peptide. This study will evaluate the effect of 26 weeks of vitamin D3 supplementation in patients with end stage renal disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
- Hemodialysis or peritoneal dialysis > 3 months
Exclusion Criteria
- Hypercalceamia
- Cancer
- Inability to give informed consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - Cholecalciferol Cholecalciferol -
- Primary Outcome Measures
Name Time Method Plasma concentration of NT-proBNP 26 weeks
- Secondary Outcome Measures
Name Time Method 24-hour blood pressure 26 weeks Plasma renin concentration 26 weeks Plasma concentration of angiotensin II 26 weeks Plasma concentration of aldosterone 26 weeks Arterial stiffness 26 weeks Serum concentration of FGF-23 26 weeks Plasma concentration of AVP 26 weeks Plasma concentration of ANP 26 weeks Plasma concentration of TNF alpha 26 weeks Heart Function 26 weeks Plasma concentration of ionized calcium 4 weeks Plasma concentration of phosphate 4 weeks Plasma concentration of PTH 4 weeks Plasma concentration of 25-hydroxycholecalciferol 4 weeks
Trial Locations
- Locations (1)
Departments of Medical Research and Medicine, Holstebro Hospital
🇩🇰Holstebro, Denmark